about
Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type MiceTau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments.Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.Mucosal vaccination delays or prevents prion infection via an oral route.Antibody-derived in vivo imaging of tau pathology.Immunization treatment approaches in Alzheimer's and prion diseases.A safer vaccine for Alzheimer's disease?A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.Specific amyloid β clearance by a catalytic antibody construct.Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhagesImmunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic miceImmunization delays the onset of prion disease in mice.Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.New directions towards safer and effective vaccines for Alzheimer's disease.Immunotherapy for conformational diseases.High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathologyAntibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance.Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.Murine models of Alzheimer's disease and their use in developing immunotherapies.Therapeutic applications of antibodies in non-infectious neurodegenerative diseasesImmunotherapy for tauopathies.Tau immunotherapy and imaging.Harnessing the immune system for treatment and detection of tau pathology.Tau immunotherapy for Alzheimer's disease.Tau Immunotherapy.Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model.A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice.Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approachIn vivo magnetic resonance imaging of amyloid-β plaques in miceBilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects.Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.Alzheimer's disease: challenges ahead.Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue.Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type.
P50
Q27329865-21C60019-924F-4FC1-B218-0F1AF16CD2B5Q30444295-2B477E0F-09F0-4E8C-ADDF-E8F1744AAB75Q30805841-6511B9AF-9FAF-4C5A-9E9C-C12A4CB294F0Q33935251-6CE0B841-6895-4E72-8D05-71FC78AF0EE3Q34416637-FDD2E0A0-375F-418A-8037-20FCD8245F8EQ34664345-D5873744-219E-4C1E-854D-6080CA2AF08FQ34778095-00A3D05C-7A0E-4917-8D18-E248C9C5CA83Q35019424-A38FA6F7-DF3D-460D-8689-E72DDF166786Q35103136-C5192F27-61BA-4806-B1E3-58DDDD08D6A9Q35451085-27556626-CFEF-49B4-97DC-19919D239ACDQ35606537-AB45ABBF-B181-4C1A-81F4-E10D2628EE2CQ35747037-5AD45823-EB86-4BCC-875B-FFDCE667F45CQ35747479-BC4CAE56-8484-4DE6-92AC-00395874449AQ36005623-96564682-04EF-4FFB-AEBC-862C9C8C558AQ36055192-68ED8FD8-66B6-4A23-8BF7-D1B83A46C9D9Q36536414-1F57E944-F8FC-465C-B6C3-E066882C26EBQ36776046-619B5DA4-6AFE-432B-9DC2-36A3800D317DQ37308949-B73AA4B5-F700-4FB6-9296-5F3183727577Q37311364-5CDA75D0-8715-425F-BFB2-32D995D4D666Q37368709-528D83E7-125D-42A2-9944-B21296535405Q37623855-EC8894B6-109A-4528-942A-777147C41D5CQ37752915-83EC72FD-B83D-4E10-9C3E-63D93C14DD4BQ37862785-82623461-611B-4AC2-B6D4-89CF6818BBE2Q37899064-A7F5E0FE-611B-4EC1-9089-253E1A441F29Q38136880-2723A9D1-9F74-41DD-9D9E-E3D4CE43035BQ38194049-88B16B28-B4B1-4737-A013-DE01E74CF22FQ38407801-CBC2A721-8400-4A8B-B5E0-04051ADF1C9CQ38628672-24E42C37-1C7B-41CB-BFFF-BCECD74CF092Q38773662-DD7FDD64-A832-4A00-9C1C-4457E54BFCEEQ38784401-744FBAF9-A869-4A6D-A91C-48DD975C6D7BQ40090247-82A1DC65-E8AF-4558-B031-2C2EFFBEC521Q40535875-B1EDEB24-2B5B-4FC8-ABEE-ADF7DAD38AB1Q41629521-5C8C9BB2-B178-4BD0-8800-5A375C21C5B0Q41768523-3990D70C-C25E-44AF-850A-18D8C5AAC393Q42672221-EBD63AB5-DF76-49ED-90D9-9D252935A79CQ42693894-BA6A18E4-0E39-4F51-B7F8-2AA9540509FAQ42699547-E49F3F08-EEF3-49D8-AE67-DB9628AD960EQ42818487-36B28D25-FF35-4856-A043-2FAEF69A7C18Q43074512-C1A8AE54-892C-4B28-A5F7-09EF2B52A87FQ43572914-CF565889-34B7-451D-ABE3-0070A774E37C
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Einar M Sigurdsson
@ast
Einar M Sigurdsson
@en
Einar M Sigurdsson
@es
Einar M Sigurdsson
@nl
Einar M Sigurdsson
@sl
type
label
Einar M Sigurdsson
@ast
Einar M Sigurdsson
@en
Einar M Sigurdsson
@es
Einar M Sigurdsson
@nl
Einar M Sigurdsson
@sl
prefLabel
Einar M Sigurdsson
@ast
Einar M Sigurdsson
@en
Einar M Sigurdsson
@es
Einar M Sigurdsson
@nl
Einar M Sigurdsson
@sl
P1006
P214
P244
P1006
P106
P1580
P21
P213
0000 0001 1713 904X
P214
P244
n2004121221
P31
P496
0000-0003-1451-0952
P7859
lccn-n2004121221